Following Array Biopharma Inc (NASDAQ:ARRY) reporting positive top line results from part 2 of a late-stage study of its combo treatment candidate for metastatic and BRAF-mutant melanoma, Leerink ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback